LeMaitre Vascular Reports Strong Q4 Results, Boosts Dividend 25%, and Authorizes $100M Share Buyback

summarizeSummary

LeMaitre Vascular reported strong Q4 2025 financial results, provided optimistic 2026 guidance, increased its quarterly dividend by 25%, and authorized a new $100 million share repurchase program.

check_boxKey Events

• Strong Q4 2025 Financial Performance

  The company reported Q4 2025 sales of $64.5 million, a 16% increase year-over-year, with operating income surging 47% to $18.8 million and diluted EPS rising 39% to $0.68. Cash also increased by $16.1 million sequentially to $359.1 million.

• Positive 2026 Financial Guidance

  LeMaitre Vascular provided optimistic full-year 2026 guidance, projecting sales between $276 million and $284 million (midpoint $280 million, +12%) and adjusted operating income between $75.0 million and $80.7 million (midpoint $77.8 million, +21%).

• Significant Quarterly Dividend Increase

  The Board of Directors approved a 25% increase in the quarterly dividend, raising it to $0.25 per share of common stock, payable on March 26, 2026.

• New Share Repurchase Authorization

  The Board authorized a new share repurchase program of up to $100.0 million of the company's common stock, valid until February 18, 2027.

auto_awesomeAnalysis

This 8-K filing signals robust financial health and strong management confidence. The company delivered impressive Q4 2025 results, significantly exceeding prior year performance across key metrics like sales, operating income, and EPS. The positive momentum is projected to continue into 2026 with solid guidance. Furthermore, the 25% dividend increase and the authorization of a substantial $100 million share repurchase program demonstrate a commitment to returning value to shareholders and suggest management believes the stock is undervalued. These combined actions are highly positive and likely to be viewed favorably by the market.